Proton Pump Inhibitors Do Not Reduce the Risk of Esophageal Adenocarcinoma in Patients with Barrett’s Esophagus: A Systematic Review and Meta-Analysis

Letter: proton pump inhibitor usage still seems to reduce the risk of high-grade dysplasia and/or oesophageal adenocarcinoma in Barrett's oesophagus - authors’ reply

(2014) F. Hvid-Jensen et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Proton pump inhibitor use may not prevent high-grade dysplasia and oesophageal adenocarcinoma in Barrett's oesophagus: a nationwide study of 9883 patients

(2014) F. Hvid-Jensen et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Role of Proton Pump Inhibitor on Esophageal Carcinogenesis and Pancreatic Acinar Cell Metaplasia Development: An Experimental In Vivo Study

(2014) Luigi Dall’Olmo et al.   PLoS One

Statin Use Is Associated With Reduced Risk of Histologic Subtypes of Esophageal Cancer: A Nested Case-Control Analysis

(2013) Leo Alexandre et al.   GASTROENTEROLOGY

Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis

(2013) Siddharth Singh et al.   GUT

British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus

(2013) Rebecca C Fitzgerald et al.   GUT

Proton Pump Inhibitors Reduce the Risk of Neoplastic Progression in Patients With Barrett's Esophagus

(2012) Florine Kastelein et al.   Clinical Gastroenterology and Hepatology

A Combination of Esomeprazole and Aspirin Reduces Tissue Concentrations of Prostaglandin E2 in Patients With Barrett's Esophagus

(2012) Gary W. Falk et al.   GASTROENTEROLOGY

Do proton pump inhibitors protect against cancer progression in GERD?

(2012) Tomoharu Miyashita et al.   SURGERY TODAY

Epidemiology and Natural History of Intestinal Metaplasia of the Gastroesophageal Junction and Barrett's Esophagus: A Population-Based Study

(2011) Kee Wook Jung et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Deoxycholic acid causes DNA damage while inducing apoptotic resistance through NF-κB activation in benign Barrett's epithelial cells

(2011) Xiaofang Huo et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Dating the Rise of Esophageal Adenocarcinoma: Analysis of Connecticut Tumor Registry Data, 1940-2007

(2011) J. A. Abrams et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Role of Acid Suppression in the Development and Progression of Dysplasia in Patients with Barrett’s Esophagus

(2011) F. Kastelein et al.   DIGESTIVE DISEASES

Time-window Bias in Case-control Studies

(2011) Samy Suissa et al.   EPIDEMIOLOGY

American Gastroenterological Association Medical Position Statement on the Management of Barrett's Esophagus

(2011)   GASTROENTEROLOGY

Acid suppression increases rates of Barrett’s esophagus and esophageal injury in the presence of duodenal reflux

(2011) Ayman O. Nasr et al.   SURGERY

Proximal and distal esophageal sensitivity is decreased in patients with Barrett’s esophagus

(2011) Anne L Krarup   WORLD JOURNAL OF GASTROENTEROLOGY

Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses

(2010) Andreas Stang   EUROPEAN JOURNAL OF EPIDEMIOLOGY

Medications (NSAIDs, Statins, Proton Pump Inhibitors) and the Risk of Esophageal Adenocarcinoma in Patients With Barrett's Esophagus

(2010) Dang M. Nguyen et al.   GASTROENTEROLOGY

Barrett's oesophagus, proton pump inhibitors and gastrin: the fog is clearing

(2010) E. J. Kuipers   GUT

Correlation between serum gastrin and cellular proliferation in Barrett’s esophagus

(2010) Daniel A. Green et al.   Therapeutic Advances in Gastroenterology

Dyspeptic Symptoms and Endoscopic Findings in the Community: The Loiano–Monghidoro Study

(2009) Rocco Maurizio Zagari et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Elevated Serum Gastrin Is Associated With a History of Advanced Neoplasia in Barrett's Esophagus

(2009) Judy S Wang et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Medication Usage and the Risk of Neoplasia in Patients With Barrett's Esophagus

(2009) Dang M. Nguyen et al.   Clinical Gastroenterology and Hepatology

Lansoprazole, a Proton Pump Inhibitor, Mediates Anti-Inflammatory Effect in Gastric Mucosal Cells through the Induction of Heme Oxygenase-1 via Activation of NF-E2-Related Factor 2 and Oxidation of Kelch-Like ECH-Associating Protein 1

(2009) T. Takagi et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Prevalence of Barrett’s Esophagus in Patients with or without GERD Symptoms: Role of Race, Age, and Gender

(2008) Xinqing Fan et al.   DIGESTIVE DISEASES AND SCIENCES

Lansoprazole Protects and Heals Gastric Mucosa from Non-steroidal Anti-inflammatory Drug (NSAID)-induced Gastropathy by Inhibiting Mitochondrial as Well as Fas-mediated Death Pathways with Concurrent Induction of Mucosal Cell Renewal

(2008) Pallab Maity et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Incidence of Adenocarcinoma of the Esophagus Among White Americans by Sex, Stage, and Age

(2008) L. M. Brown et al.   JNCI-Journal of the National Cancer Institute